Vita Life Sciences (VLS) H2 2024 earnings summary

Executive summary

• Achieved record revenue of $79.5m, up 8.3% year-over-year, with strong growth in Australia, Malaysia, and Singapore, but weaker performance in China due to a business reset.

• Profit before tax was $12.6m, up 1.5% year-over-year, while net profit after tax declined 3.3% to $8.8m due to increased investment in marketing and expansion.

• Cash balance rose 16.1% to $28.6m, and total equity increased 20.6% to $52.3m at year-end.

• Fully franked dividend of 10.0 cents per share declared, up 11.1%, marking the 15th consecutive year of dividend payments.

Financial highlights

• Sales revenue: $79.5m (+8.3% YoY); profit before tax: $12.6m (+1.5% YoY); net profit after tax: $8.8m (-3.3% YoY).

• Earnings per share: 15.8 cents (-6.7% YoY).

• Net cash balance: $28.6m (+16.1% YoY); total equity: $52.3m (+20.6% YoY).

• Gross profit margin improved to $47.2m from $42.4m YoY.

Outlook and guidance

• Focus on expanding in Vietnam, Indonesia, and China, with increased investment expected to impact short-term profitability but drive medium-term growth.

• Continued commitment to product quality, innovation, and sustainable sourcing to meet rising global demand.

• Directors remain confident in strategies and management, aiming for improved shareholder returns.